stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (94.85%) | (1,203.00%) | (1,037.51%) | — |
+3 more TTM periods Free account |
|
| (40.66%) | (230.19%) | (205.27%) | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(46.88%) | (802.86%) | (805.79%) | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.21) | (0.19) | (0.30) | |
Free Cash Flow |
(18.39) | (17.06) | (13.96) | (21.80) | |
| Other line items | |||||
Cash ROIC |
(19.05%) | (105.93%) | (69.70%) | (355.20%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Operating CF/Net income |
1.17 | 0.57 | 0.44 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.21) | (0.19) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026